LDS/Medical Tests/Niemann-Pick Disease, Types A and B, Gene Mutation Analysis

Niemann-Pick Disease, Types A and B, Gene Mutation Analysis

Niemann-Pick Disease Type C (NPC) is an autosomal recessive neurodegenerative lysosomal storage disease resulting in impaired intracellular cholesterol and lipid transport. Disease symptoms may present in infants, children and adults and typically include: splenomegaly, ataxia, seizures, dementia, progressive neurological deterioration, and gelastic cataplexy. The estimated incidence of NPC disease is 1:150,000 live births, with an increased risk for certain populations including: French Acadians in Nova Scotia, Hispanics in specific areas of Colorado and New Mexico, as well as small Bedouin groups in Israel.

Two different mutations have been associated with NPC disease. Mutations of the NPC1 gene located on chromosome 18q11 account for 95% of known cases. A smaller fraction of known cases can be attributed to a mutation of the NPC2 gene, located on chromosome 14q24.3.  NPC1 is a transmembrane protein and NPC2 is a soluble protein plain role in lipid transport in lysosomes. Mutations in the NPC1 gene lead to a failure of the calcium-mediated fusion of endosomes with lysosomes leading to loss of function, which then result in the accumulation of cholesterol and other lipids in endosomes and lysosomes. Currently, no cure exists for NPC. Treatment consists of symptom-based supportive care.

  • Carrier testing for at risk relatives – requires prior identification of familial disease-causing mutations
  • Prenatal and preimplantation genetic diagnosis (PGD) for at risk pregnancies – requires prior identification of familial disease-causing mutations
  • Diagnostic testing for symptomatic patients
  • Confirmatory testing for patients with a biochemical diagnosis of Niemann-Pick Disease Type C
  • Mutations of the NPC1 and NPC2 gene are reported as either detected or absent. Mutations of the NPC1 gene account for approximately 95% of patients and NPC2 mutations account for the remaining 5%.
  • Detected mutations are reported with sequence changes identified, and as heterozygous or homozygous and are indicative of diagnosis
  • Most patients with NPC1 mutations are compound heterozygotes
  • Rare polymorphisms exist that may lead to false negative or positive results
  • Mutations of the NPC1 or NPC2 genes are found in 94% of those with the disease. Correlation with patient’s medical history, family history, and other diagnostic test results is recommended

Negative for mutations analyzed (No mutation detected)

Real-time PCR and ARMS, multiplex ligation-dependent probe amplification (MLPA), chromosomal microarray (CMA), capillary sequencing with reflex to exon array, Next generation sequencing (NGS).

Whole blood collected in EDTA (lavender top tubes).

Fibroblast lysosomal enzyme screening: (2) T-24 flasks of cultured skin fibroblasts filled with culture media, room temperature.

Prenatal screening with a previously identified mutation: amniotic fluid or chorionic villi in transport media. Prenatal specimens should be refrigerated, and accompanied by a maternal blood sample.

Stability

  • Ambient: 1-3 days
  • Refrigerated: 7 days
Biochemical testing for demonstration of impaired esterification in cultured fibroblasts (e.g., filipin staining) is the primary method of diagnosis (followed by confirmatory genetic testing), Ashkenazi Jewish panel genetic screening, Bloom's Syndrome, Gaucher Disease, Liver functional panel, and Genetic counseling, CBC (may show anemia and/or thrombocytopenia), Bone marrow biopsy with examination for vacuolated histiocytes (no longer used to diagnose with the advent of biochemical and molecular testing). Electron microscopy of skin or rectal biopsy.
7–14 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login